Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients

International Journal of Urology

Volumn 7, Issue 9, 2000, Pages 321-329

  Mita, Koji ^a,b   Nakahara, Mitsuru ^a   Usui, Tsuguru ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Carcinoma; Insulin like growth factor; Insulin like growth factor system; Prostate

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; RNA, MESSENGER;

EID: 0033796106     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00200.x     Document Type: Article

References (18)

1. The insulin-like growth factor system in the prostate
2. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6)
3. Binding proteins for the insulin-like growth factors. Structure, regulation and function
4. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
5. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture
6. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
7. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
8. Insulin-like growth factor-binding protein (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization
9. Single-step method of RNA isolation by acid guanidium thiocyanate-phenolchloroform extraction
10. Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs
11. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma
12. Insulin-like growth factor II mRNA expression in human breast cancer
13. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines. LNCaP, DU145 and PC-3 cells
14. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC3)
15. Cloning and sequence determination of insulin-like growth factor binding protein-2 (IGFBP): Comparison with IGFBP-1
16. Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors
17. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
18. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor